Review Article 
Canine Prostate Cancer: Would the Dog be an Important Model for the Study of New Drugs?
Carlos Eduardo Fonseca-Alves, Igor Simoes Tiagua Vicente, Sabryna Gouveia Calazans and Renee Laufer-Amorim
American Journal of Drug Discovery and Development, 2013, 3(4), 220-224.
Abstract
Prostate cancer is ranked as the second leading cause of cancer-related death in men aged above 50 years and the long-term survival of patients with metastatic disease has not changed significantly. This fact is related mainly to the limited therapeutic options available. Despite numerous studies on PCa in humans, success was not obtained in clinical trials of targeted therapies because of the difficulty in standardizing an ideal animal model for application in clinical trials. The use of dogs as a model for the clinical trials of new drugs can bring in higher accuracy in assessing the response of tumors to the drugs tested, with the assumption that the dog is a natural model of the disease and shares the same environment as humans. Due of the importance of prostate carcinoma in man the goal of the review is to identify the strengths of the dog as a model for the development of new therapy for prostatic carcinoma.
ASCI-ID: 2817-74
Similar Articles
Role of C-Peptide in Development of Diabetic Neuropathy [DN] Animal Model
American Journal of Drug Discovery and Development, 2014, 4(1), 12-21.
Cited By
Association of CD44+/CD24-Cells to More Aggressive Molecular Phenotypes in Canine Mammary Carcinomas
International Journal of Cancer Research, 2015, 11(3), 119. DOI: 10.3923/ijcr.2015.119.127
Metronomic Chemotherapy in Small Animal Practice: An UpdateAsian Journal of Animal and Veterinary Advances, 2015, 11(1), 17. DOI: 10.3923/ajava.2016.17.23
Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinomaTranslational and Regulatory Sciences, 2021, 3(1), 1. DOI: 10.33611/trs.2020-018
RNA-seq of nine canine prostate cancer cell lines reveals diverse therapeutic target signaturesCancer Cell International, 2022, 22(1), 54. DOI: 10.1186/s12935-021-02422-9
MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell LinesInternational Journal of Molecular Sciences, 2023, 24(9), 8136. DOI: 10.3390/ijms24098136
Tumor–Microenvironment Interaction: Analysis of Mast Cell Populations in Normal Tissue and Proliferative Disorders of the Canine ProstateVeterinary Sciences, 2019, 6(1), 16. DOI: 10.3390/vetsci6010016
An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate GenesInternational Journal of Molecular Sciences, 2021, 22(21), 11481. DOI: 10.3390/ijms222111481
Evidence of epithelial–mesenchymal transition in canine prostate cancer metastasisResearch in Veterinary Science, 2015, 100(), 176. DOI: 10.1016/j.rvsc.2015.03.001
Canine prostate cancer cell transcriptome reveals important dysregulation in PI3K/AKT/mTOR pathwayJournal of Comparative Pathology, 2025, 219(), 52. DOI: 10.1016/j.jcpa.2025.03.190
In vivo optoacoustic temperature imaging for image-guided cryotherapy of prostate cancerPhysics in Medicine & Biology, 2018, 63(6), 064002. DOI: 10.1088/1361-6560/aab241